The Japanese company entered the lucrative US market by the hand of Shire through the big door and, according to forecasts, it will make a record profit in 2021 thanks to treatments such as Entyvio or Vyvanse. The second half of the decade looks promising.
The Japanese firm plans to launch 12 new treatments in 2024, and just a month ago it announced revenue expectations for 2030 of 5 trillion yen (about 38.2 billion euros at the current exchange rate).
